Platelet-rich plasma (PRP) is a product that contains a large number of platelets in a small plasma volume. PRP works as a fibrin tissue adhesive with tissue sealing and hemostatic characteristics. PRP differs from platelet-poor tissue and fibrin glue because it provides a unique ability to augment the wound healing process and osteogenesis. PRP functions as a safe, biocompatible, prompt hemostatic agent and fast-tracks epidermal, epithelial, and endothelial regeneration. PRP enhances collagen synthesis, encourages angiogenesis, reduces dermal scarring, augments soft tissue healing, and reverses inhibition of glucocorticoid-induced healing. The high concentration of leukocytes in PRP offers an additional antimicrobial effect.
PRP offers a wide range of clinical healing uses in otolaryngology, general surgery, cosmetic surgery, aesthetics, burn and wound healing, cardiovascular surgery, oral and maxillofacial surgical procedures, and others. PRP has proven effective in treating chronic non-healing wounds and has been adopted as an antiangiogenic agent. In surgical procedures, PRP reduces the risk of postoperative and preoperative bleeding both at donor and recipient sites; it augments soft tissue healing and facilitates stability of grafted tissue at the recipient site owing to its adhesive and cohesive properties.
The global platelet-rich plasma market is segmented on the following bases:
Type
pure platelet-rich plasma (P-PRP)
leukocyte-platelet-rich plasma (L-PRP)
Leukocyte-Platelet Rich Fibrin (L-PRF)
Origin
Allogeneic
Autologous
Homologous
Clinical Applications
General Surgery
Neurosurgery
Cosmetic Surgery and Aesthetics
orthopedic and spinal surgery
Others (Otorhinolaryngology-Head and Neck Surgery, Oral and Maxillofacial Surgery, Periodontal Surgery, Urology, Cardiothoracic Surgery, etc.)
Geography
North America
U.S.
Canada
Europe
Germany
France
Italy
U.K.
Russia
Rest of Europe
Asia-Pacific
India
China
Japan
Rest of Asia-Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
GCC Countries
South Africa
Rest of Middle East and Africa
Key players identified for the platelet-rich plasma market include but are not limited to:
Arthrex, Inc., Arteriocyte Medical Systems, Inc., DePuy Synthes, Inc., Biomet, Inc., Cesca Therapeutics, Inc., Dr. PRP America LLC, EmCyte Corporation, AdiStem Ltd., Exactech, Inc., Nuo Therapeutics, Inc., Regen Lab SA, Harvest Technologies Corp., and several others
This report offers the following:
An overview of the global markets for platelet-rich plasma
Market trends assessment for the period 2013-2023, with historical information for 2013 and 2014 and projections through 2023, with respective CAGRs during 2016 and 2023
Qualitative assessment tools such as market drivers, challenges, future prospects, major commercial events, etc.
Market competition scrutiny tools such as market share assessment, an attractive investment proposition, and others
Focus on each level of market segmentation based on product approvals, launches, and current and anticipated market dynamics.
A general overview of the industry structure
Company profiles highlight key information about the major players operating in the platelet-rich plasma market.
Frequently Asked Questions:
The market for Platelet Rich Plasma (PRP) Market is expected to reach XX Bn in 2023.
The Platelet Rich Plasma (PRP) Market is expected to see significant CAGR growth over the coming years, at XX%.
